

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Novita Healthcare Limited (**Novita**)

ABN

53 108 150 750

We (the entity) give ASX the following information.

### Part 1 - All issues

*You must complete the relevant sections (attach sheets if there is not enough space).*

- |   |   |   |
|---|---|---|
| 1 | +Class of +securities issued or to be issued  | Fully Paid Ordinary Shares<br><br>Unlisted Options  |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued | 99,999,999 Fully Paid Ordinary Shares issued pursuant to Novita's placement announced to the ASX on 25 November 2019 ( <b>Placement</b> ).<br><br>7,188,882 Unlisted Options ( <b>Broker Options</b> )<br><br>14,377,766 Unlisted Options ( <b>Employee Options</b> ) |

+ See chapter 19 for defined terms.

## Appendix 3B

### New issue announcement

---

- |  |   |
|--|---|
| <p>3 Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)</p> | <p>Fully Paid Ordinary Shares ranking equally in all respects with existing ordinary shares.</p> <p>Broker Options - Unlisted Options with an exercise price of \$0.09 and an expiry date of 30 June 2022.</p> <p>Employee Options - Unlisted Options with an exercise price of \$0.03 and an expiry date of 3 October 2022</p> |
|--|---|

---

+ See chapter 19 for defined terms.

<p>4 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?</p> <p>If the additional +securities do not rank equally, please state:</p> <ul style="list-style-type: none"> <li>• the date from which they do</li> <li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	<p>Fully Paid Ordinary Shares - Yes</p> <p>Broker Options and Employee Options - Any shares issued upon exercise of the options will rank equally with the existing fully paid ordinary shares in Novita.</p>
<p>5 Issue price or consideration</p>	<p>Fully Paid Ordinary Shares - \$0.062 per share</p> <p>Broker Options and Employee Options - Nil per option</p>
<p>6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>	<p>Fully Paid Ordinary Shares - The funds raised from the Placement will be used to accelerate U.S. marketing and sales, along with commercial activities in Australia, Europe &amp; UK. Novita will also investigate the use of the TALi technology in other neurological areas along with supporting working capital requirements.</p> <p>Broker Options - Issued as part of the fees payable to PAC Partners Securities Pty Limited in connection with its role as lead manager under the Placement.</p> <p>Employee Options - Issued to the Managing Director as approved at the AGM held on 26 November 2019. These Options replace 14,377,766 cancelled Options previously issued to the Managing Director. For further details, refer to the Notice of AGM announced to ASX on 24 October 2019.</p>

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

<p>6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?</p> <p>If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i</p>	<p>Yes</p>
<p>6b The date the security holder resolution under rule 7.1A was passed</p>	<p>26 November 2019</p>
<p>6c Number of +securities issued without security holder approval under rule 7.1</p>	<p>35,069,478 Fully Paid Ordinary Shares 7,188,882 Broker Options</p>
<p>6d Number of +securities issued with security holder approval under rule 7.1A</p>	<p>64,930,521 Fully Paid Ordinary Shares</p>
<p>6e Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)</p>	<p>Nil</p>
<p>6f Number of +securities issued under an exception in rule 7.2</p>	<p>14,377,766 Employee Options</p>
<p>6g If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.</p>	<p>Yes</p>
<p>6h If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements</p>	<p>Not applicable</p>
<p>6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements</p>	<p>55,137,422 (under rule 7.1) 0 (under rule 7.1A) 55,137,422 (total)</p>

+ See chapter 19 for defined terms.

7	<p><b>+Issue dates</b></p> <p>Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.</p> <p>Cross reference: item 33 of Appendix 3B.</p>	<p>Fully Paid Ordinary Shares and Broker Options - 29 November 2019</p> <p>Employee Options - 2 December 2019</p>	
8	<p>Number and <b>+class</b> of all <b>+securities</b> quoted on ASX (<i>including</i> the <b>+securities</b> in section 2 if applicable)</p>	Number	<b>+Class</b>
		749,305,218	Fully Paid Ordinary Shares
9	<p>Number and <b>+class</b> of all <b>+securities</b> not quoted on ASX (<i>including</i> the <b>+securities</b> in section 2 if applicable)</p>	Number	<b>+Class</b>
		14,377,766 13,600,000 6,800,000 10,974,389	Employee Options Director Options Vendor Options Broker Options
10	<p>Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)</p>	Ranks equally with all other securities.	

## Part 2 - Pro rata issue

11	<p>Is security holder approval required?</p>	Not applicable
12	<p>Is the issue renounceable or non-renounceable?</p>	Not applicable
13	<p>Ratio in which the <b>+securities</b> will be offered</p>	Not applicable
14	<p><b>+Class</b> of <b>+securities</b> to which the offer relates</p>	Not applicable
15	<p><b>+Record</b> date to determine entitlements</p>	Not applicable

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	Not applicable
17	Policy for deciding entitlements in relation to fractions	Not applicable
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	Not applicable
19	Closing date for receipt of acceptances or renunciations	Not applicable
20	Names of any underwriters	Not applicable
21	Amount of any underwriting fee or commission	Not applicable
22	Names of any brokers to the issue	Not applicable
23	Fee or commission payable to the broker to the issue	Not applicable
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	Not applicable
25	If the issue is contingent on security holders' approval, the date of the meeting	Not applicable
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	Not applicable
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	Not applicable

---

+ See chapter 19 for defined terms.

28	Date rights trading will begin (if applicable)	Not applicable
29	Date rights trading will end (if applicable)	Not applicable
30	How do security holders sell their entitlements <i>in full</i> through a broker?	Not applicable
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	Not applicable
32	How do security holders dispose of their entitlements (except by sale through a broker)?	Not applicable
33	<sup>+</sup> Issue date	Not applicable

### Part 3 - Quotation of securities

*You need only complete this section if you are applying for quotation of securities*

- 34 Type of <sup>+</sup>securities  
(tick one)
- (a)  <sup>+</sup>Securities described in Part 1
- (b)  All other <sup>+</sup>securities
- Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

#### Entities that have ticked box 34(a)

*Tick to indicate you are providing the information or documents*

- 35  If the <sup>+</sup>securities are <sup>+</sup>equity securities, the names of the 20 largest holders of the additional <sup>+</sup>securities, and the number and percentage of additional <sup>+</sup>securities held by those holders
- 36  If the <sup>+</sup>securities are <sup>+</sup>equity securities, a distribution schedule of the additional <sup>+</sup>securities setting out the number of holders in the categories

<sup>+</sup> See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

1 - 1,000  
1,001 - 5,000  
5,001 - 10,000  
10,001 - 100,000  
100,001 and over

37  A copy of any trust deed for the additional +securities

---

+ See chapter 19 for defined terms.



**Quotation agreement**

- 1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.
  
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.  
Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
  - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
  - If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
  
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
  
- 4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Date: 3 December 2019



Print name: Stephen Denaro  
(Company secretary)

== == == == ==

---

+ See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

### Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

<b>Rule 7.1 – Issues exceeding 15% of capital</b>	
<b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>	
<b>Insert</b> number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	449,305,165
<b>Add</b> the following:	
• Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2	110,139,021
• Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval	89,861,033
• Number of partly paid +ordinary securities that became fully paid in that 12 month period	Not applicable
<b>Note:</b>	
• <i>Include only ordinary securities here – other classes of equity securities cannot be added</i>	
• <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i>	
• <i>It may be useful to set out issues of securities on different dates as separate line items</i>	
<b>Subtract</b> the number of fully paid +ordinary securities cancelled during that 12 month period	Not applicable
<b>“A”</b>	649,305,219

+ See chapter 19 for defined terms.

<b>Step 2: Calculate 15% of “A”</b>	
“B”	0.15 <i>[Note: this value cannot be changed]</i>
<b>Multiply “A” by 0.15</b>	97,395,782
<b>Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used</b>	
<p><b>Insert</b> number of +equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> <li>• Under an exception in rule 7.2</li> <li>• Under rule 7.1A</li> <li>• With security holder approval under rule 7.1 or rule 7.4</li> </ul> <p><i>Note:</i></p> <ul style="list-style-type: none"> <li>• <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i></li> <li>• <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	<p>35,069,478</p> <p>7,188,882</p>
“C”	42,258,360
<b>Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1</b>	
<p>“A” x 0.15</p> <p><i>Note: number must be same as shown in Step 2</i></p>	97,395,782
<p><b>Subtract “C”</b></p> <p><i>Note: number must be same as shown in Step 3</i></p>	42,258,360
<p><b>Total</b> [“A” x 0.15] – “C”</p> <p><i>[Note: this is the remaining placement capacity under rule 7.1]</i></p>	55,137,422

+ See chapter 19 for defined terms.

## Part 2

<b>Rule 7.1A – Additional placement capacity for eligible entities</b>	
<b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>	
<b>“A”</b>  <i>Note: number must be same as shown in Step 1 of Part 1</i>	649,305,219
<b>Step 2: Calculate 10% of “A”</b>	
<b>“D”</b>	0.10  <i>Note: this value cannot be changed</i>
<b>Multiply “A” by 0.10</b>	64,930,521
<b>Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used</b>	
<b>Insert</b> number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A  <i>Notes:</i> <ul style="list-style-type: none"> <li>• <i>This applies to equity securities – not just ordinary securities</i></li> <li>• <i>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	64,930,521
<b>“E”</b>	Nil

+ See chapter 19 for defined terms.

<b>Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A</b>	
“A” x 0.10  <i>Note: number must be same as shown in Step 2</i>	64,930,521
<b>Subtract “E”</b>  <i>Note: number must be same as shown in Step 3</i>	64,930,521
<b>Total</b> [“A” x 0.10] – “E”	0  <i>Note: this is the remaining placement capacity under rule 7.1A</i>

---

+ See chapter 19 for defined terms.